Edition:
United Kingdom

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

136.68USD
16 Jul 2018
Change (% chg)

$-2.74 (-1.97%)
Prev Close
$139.42
Open
$139.64
Day's High
$139.64
Day's Low
$135.62
Volume
261,635
Avg. Vol
502,002
52-wk High
$176.44
52-wk Low
$32.80

Select another date:

Tue, Jun 19 2018

Sarepta shares soar as Duchenne gene therapy shows promise

Sarepta Therapeutics' shares jumped 60 percent on Tuesday after promising results from a gene therapy study positioned the specialty drugmaker as a potential leader in the market for Duchenne muscular dystrophy (DMD) treatments.

UPDATE 3-Sarepta shares soar as Duchenne gene therapy shows promise

* Sarepta shares rise as much as 67.7 percent (Adds details on study results, updates share price)

BRIEF-Sarepta And Invitae Expand Partnership To Advance Clinical Research In Duchenne Muscular Dystrophy

* SAREPTA AND INVITAE EXPAND PARTNERSHIP TO ADVANCE CLINICAL RESEARCH IN DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage:

BRIEF-Sarepta Therapeutics Reports Q1 Loss Per Share Of $0.28

* SAREPTA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS

BRIEF-Sarepta Therapeutics Announces Partnership With Myonexus Therapeutics

* SAREPTA THERAPEUTICS ANNOUNCES PARTNERSHIP WITH MYONEXUS THERAPEUTICS FOR THE ADVANCEMENT OF MULTIPLE GENE THERAPY PROGRAMS AIMED AT TREATING DISTINCT FORMS OF LIMB-GIRDLE MUSCULAR DYSTROPHIES

BRIEF-Sarepta Therapeutics Inc Says CEO Douglas Ingram's 2017 Total Compensation Was $56.9 Million

* SAREPTA THERAPEUTICS INC SAYS CEO DOUGLAS INGRAM'S 2017 TOTAL COMPENSATION WAS $56.9 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2I3lSGe) Further company coverage:

BRIEF-Sarepta Therapeutics Announces Plan To Submit A New Drug Application For Accelerated Approval Of Golodirsen

* SAREPTA THERAPEUTICS ANNOUNCES PLAN TO SUBMIT A NEW DRUG APPLICATION (NDA) FOR ACCELERATED APPROVAL OF GOLODIRSEN (SRP-4053) IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) AMENABLE TO SKIPPING EXON 53

BRIEF-Sarepta Therapeutics Reports Q4 Non-GAAP Loss Per Share $0.28

* SAREPTA THERAPEUTICS ANNOUNCES FOURTH QUARTER 2017 AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS

Select another date: